Can cancer cause hair loss? It is a question many patients and their families ask, and the answer is nuanced. Whilst cancer itself rarely causes hair loss directly, the treatments used to fight it — particularly chemotherapy and radiotherapy — are among the most common culprits. Hair follicles, being rapidly dividing cells, are highly vulnerable to these therapies. In some cases, hormonal disruption from certain cancers or advanced illness may also contribute to hair shedding. This article explains the causes, what to expect during and after treatment, and the support available through the NHS.

How Cancer and Its Treatments Can Cause Hair Loss

Cancer treatments — particularly chemotherapy — are the primary cause of cancer-related hair loss, as these drugs damage rapidly dividing hair follicles. Cancer itself only rarely causes hair loss directly, through hormonal disruption or scalp involvement.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss, known medically as alopecia, is one of the most recognised and emotionally significant side effects associated with cancer and its treatment. It is important to understand, however, that cancer itself rarely causes hair loss directly. In most cases, it is the treatments used to fight cancer — rather than the disease itself — that disrupt the normal hair growth cycle.

Hair follicles are among the most rapidly dividing cells in the human body. Chemotherapy drugs, which are designed to target fast-dividing cancer cells, cannot always distinguish between malignant cells and healthy ones. As a result, hair follicles are frequently affected, leading to partial or complete hair loss from the scalp, eyebrows, eyelashes, and body.

There are some exceptions where cancer itself may contribute to hair changes. Certain cancers that affect hormone levels — such as adrenal tumours or some ovarian cancers — can disrupt the hormonal environment and lead to hair thinning. In rare cases, cancers directly involving the scalp (such as cutaneous T-cell lymphoma or scalp metastases) or paraneoplastic processes may cause localised hair loss, usually alongside other signs and symptoms. Additionally, advanced illness, significant weight loss, and nutritional deficiencies associated with cancer can all contribute to diffuse hair shedding. However, these are secondary effects rather than a direct consequence of tumour biology in most cases.

It is also worth noting that new or unexplained hair loss in someone without a known cancer diagnosis is rarely a sign of cancer. If you are experiencing unexplained hair loss — particularly alongside other symptoms such as unintentional weight loss, persistent fevers or night sweats, or an unexplained lump — you should speak to your GP.

Understanding the distinction between cancer-related and treatment-related hair loss is clinically important, as it helps patients set realistic expectations and plan appropriately. Healthcare teams, including oncology nurses and specialist pharmacists, play a key role in preparing patients for what to expect before treatment begins. Further information is available from NHS patient resources, Cancer Research UK, and Macmillan Cancer Support.

Which Cancer Treatments Are Most Likely to Affect Hair

Chemotherapy, especially anthracyclines and taxanes, carries the highest risk of significant hair loss. Radiotherapy, targeted therapies, immunotherapy, and hormone treatments can also cause alopecia or hair thinning to varying degrees.

Not all cancer treatments carry the same risk of hair loss, and the likelihood and severity of alopecia depend largely on the type, dose, and combination of therapies used.

Chemotherapy is the most common cause of treatment-related hair loss. Certain agents are particularly associated with significant alopecia, including:

• Anthracyclines (e.g., doxorubicin)

• Taxanes (e.g., docetaxel, paclitaxel)

• Cyclophosphamide

• Etoposide

These drugs interfere with cell division, causing hair follicles to enter a resting or shedding phase prematurely. Hair loss typically begins within two to four weeks of starting chemotherapy. It is important to note that a small number of patients treated with taxanes — particularly docetaxel — have experienced persistent alopecia that did not fully resolve after treatment ended. This is noted in the medicine's Summary of Product Characteristics (SmPC). If you are concerned about persistent hair loss after completing chemotherapy, speak to your oncology team or GP.

Have questions about your medication? Our pharmacists are here to help →

Radiotherapy can also cause hair loss, but this is usually localised to the area being treated. For example, radiotherapy to the head or neck may cause scalp hair loss, whilst treatment to other body areas may affect hair in those specific regions. Unlike chemotherapy-related alopecia, radiation-induced hair loss may sometimes be permanent, particularly at higher cumulative doses to the scalp. Patients should be counselled about this possibility before radiotherapy begins.

Targeted therapies carry a variable but notable risk of hair changes. Examples include:

• EGFR inhibitors (e.g., erlotinib, gefitinib): may cause hair thinning, alopecia, or changes in hair texture and growth patterns

• Hedgehog pathway inhibitors (e.g., vismodegib, sonidegib): alopecia is a commonly reported side effect

• BRAF and MEK inhibitors (e.g., vemurafenib, dabrafenib): associated with hair thinning or texture changes

• VEGF/multikinase inhibitors (e.g., sunitinib, sorafenib): hair depigmentation and thinning have been reported

• CDK4/6 inhibitors (e.g., palbociclib, ribociclib): alopecia or hair thinning may occur

Immunotherapy (immune checkpoint inhibitors) carries a lower overall risk of hair loss, but can occasionally trigger immune-related alopecia areata — a patchy pattern of hair loss caused by an autoimmune response. If you notice patchy hair loss whilst receiving immunotherapy, report this to your oncology team promptly, as it may require specific management.

Hormone therapies, such as those used in breast or prostate cancer, may cause gradual hair thinning similar to androgenetic alopecia, though this is generally less severe than chemotherapy-induced hair loss. Hair thinning may persist for as long as hormone therapy continues.

Patients should always discuss the specific hair-related side effects of their individual treatment plan with their oncology team before commencing therapy. If you experience unexpected side effects from any medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What to Expect: Hair Loss During and After Treatment

Hair loss typically begins within two to four weeks of starting chemotherapy, affecting the scalp, eyebrows, eyelashes, and body hair. The extent varies between individuals and can have a significant psychological impact.

For many patients, hair loss begins gradually, often noticed first as increased shedding on the pillow, in the shower, or when brushing. This typically occurs within two to four weeks of starting chemotherapy, though the exact timing varies depending on the drug regimen. Some patients experience a sudden, more dramatic loss, whilst others notice a slower, progressive thinning over several weeks.

Hair loss may affect the entire scalp or occur in patches. Beyond the scalp, patients may also lose eyebrows, eyelashes, nasal hair, and body hair. Loss of nasal hair can lead to increased nasal discharge; a gentle saline nasal spray or a small amount of soft paraffin at the nostril entrance may help manage this. Loss of eyelashes can cause eye irritation and increased sensitivity — preservative-free artificial tears and protective eyewear (such as sunglasses outdoors) can offer some relief. Losing eyebrows and eyelashes can be particularly distressing, as these features significantly affect facial appearance and expression.

It is worth noting that the degree of hair loss is not uniform across all patients, even those receiving the same treatment. Factors such as individual follicle sensitivity, overall health, and the specific drug combination all influence the extent of alopecia. Some patients on lower-dose regimens may experience only mild thinning.

Emotionally, hair loss can have a profound psychological impact. Macmillan Cancer Support and the NHS both acknowledge that alopecia is one of the most distressing side effects of cancer treatment, affecting self-image, identity, and quality of life. Patients are advised to speak openly with their clinical nurse specialist or oncology team about their concerns, as early support — including referral to psychological services — can make a meaningful difference to wellbeing throughout treatment.

Managing Hair Loss: NHS Support and Practical Options

Scalp cooling is the most evidence-based option to reduce chemotherapy-induced hair loss and is available in many NHS units. NHS wig vouchers, counselling, and practical self-care measures are also available to support patients.

The NHS provides a range of support options for patients experiencing treatment-related hair loss, and patients are encouraged to explore these early — ideally before hair loss begins.

Scalp cooling (also known as cold cap therapy) is one of the most evidence-based interventions available. By reducing blood flow to the scalp during chemotherapy infusions, scalp cooling can limit the amount of drug reaching hair follicles, thereby reducing hair loss in some patients. It is available in many NHS chemotherapy units, but it is not suitable for all cancers or chemotherapy regimens. In particular, scalp cooling is generally not offered for many blood cancers (such as leukaemia and lymphoma), where cancer cells may circulate in the bloodstream and scalp vessels. Its effectiveness also varies between individuals and drug regimens. Patients should discuss eligibility and suitability with their oncology team before treatment begins. Further information is available from Macmillan Cancer Support and the NHS.

For those who do experience significant hair loss, support may include:

• Wigs: The NHS may contribute towards the cost of a wig through a surgical appliance voucher. Provision and charges vary across the UK — wigs are available free of charge in Scotland, Wales, and Northern Ireland, whilst patients in England may be charged unless they qualify for help with health costs (for example, those receiving certain benefits or with a valid HC2 certificate). The NHS Business Services Authority (NHSBSA) provides up-to-date guidance on eligibility and charges at nhsbsa.nhs.uk. Local voucher schemes and wig-fitting services, often provided by specialist nurses or appliance officers, may also be available through your NHS trust.

• Support groups and counselling through Macmillan Cancer Support, Maggie's Centres, or local NHS psychological support services

Practical self-care measures can also help patients feel more comfortable:

• Use a mild shampoo and a soft-bristle brush; avoid heat styling and chemical treatments (such as perming or colouring) during treatment

• Wear soft cotton or bamboo head coverings at night to reduce scalp irritation

• Protect the scalp from sun exposure with hats or a broad-spectrum SPF product

• Explore headscarves, turbans, or hats as alternatives or complements to wigs

After completing chemotherapy, topical minoxidil has been used by some patients to help speed up hair regrowth, though it will not prevent hair loss during treatment. This should only be considered after discussion with your oncology or dermatology team.

Macmillan Cancer Support, Cancer Research UK, and the charity Alopecia UK all offer guidance and peer support. Patients are encouraged to contact their clinical nurse specialist if hair loss is causing significant distress, as psychological support referrals can be arranged through the NHS.

When Hair Regrows and What the Recovery Process Looks Like

Hair regrowth typically begins within weeks to three months of completing chemotherapy, often returning with a different texture initially. Radiotherapy-induced hair loss may be permanent at higher doses, and persistent loss beyond six months warrants medical review.

For the majority of patients who experience chemotherapy-induced hair loss, hair regrowth typically begins within a few weeks to three months of completing treatment, though the timeline varies considerably between individuals. Full thickness and length can take many months to return, and it is important to set realistic expectations about the pace of recovery.

Many patients notice that their hair grows back with a different texture — often softer, curlier, or finer than it was previously. This phenomenon is sometimes referred to colloquially as 'chemo curls'. In most cases, hair gradually returns to its original texture over the following months, though for some individuals the change may be longer-lasting. Hair colour may also differ temporarily, appearing lighter or darker during the early regrowth phase.

A small number of patients — particularly those who have received certain taxane-based regimens such as docetaxel — may experience persistent alopecia that does not fully resolve. If your hair has not begun to regrow within six months of completing chemotherapy, or if you are concerned about the pattern or quality of regrowth, contact your GP or oncology team. It is worth checking for other treatable causes of delayed regrowth, such as thyroid dysfunction, iron deficiency, or low vitamin B12 — your GP can arrange appropriate blood tests. A referral to a dermatologist may also be appropriate.

For patients who have received radiotherapy to the scalp, regrowth is less predictable. At lower radiation doses, hair may regrow within three to six months. At higher cumulative doses, hair follicles may be permanently damaged, resulting in lasting hair loss in the treated area. Patients should be counselled about this possibility before radiotherapy begins, particularly when treatment involves the head or neck.

Regrowth timelines for targeted therapies and hormone treatments vary considerably. Hair thinning associated with hormone therapy may persist for as long as the treatment continues.

During the regrowth phase, treat new hair gently: use a mild shampoo, avoid heat styling tools, and delay harsh chemical treatments such as bleaching, perming, or colouring until hair has regained reasonable strength and thickness — usually several months after regrowth begins.

Throughout recovery, continued emotional support remains important. Patients should feel empowered to seek help if they are struggling with the psychological impact of changes to their appearance. Macmillan Cancer Support and NHS psychological services can provide ongoing assistance. If you experience unexpected or persistent side effects from any medicine during or after treatment, report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions